APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy

Colorectal Cancer (CRC) is highly heterogeneous for which prognosis is dependent mainly on clinical staging. There is a need to stratify subpopulations of CRC on molecular basis to better predict outcome and therapy response. Truncating mutations in adenomatous polyposis coli (APC) are well-describe...

Full description

Bibliographic Details
Main Authors: Abdul K. Siraj, Sandeep Kumar Parvathareddy, Poyil Pratheeshkumar, Sasidharan Padmaja Divya, Saeeda Omer Ahmed, Roxanne Melosantos, Rafia Begum, Rica Micaela J.A. Concepcion, Nasser Al-Sanea, Luai H Ashari, Alaa Abduljabbar, Fouad Al-Dayel, Khawla S. Al-Kuraya
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
APC
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332219351947